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Trends in Stage Distribution for Patients with Non-small
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Daniel Morgensztern, MD,*†‡ Shean Huey Ng,† Feng Gao, MD, PhD,§ and
Ramaswamy Govindan, MD†‡
Introduction:We examined the recent changes in stage distribution
in newly diagnosed patients with non-small cell lung cancer
(NSCLC) using a national database to assess the impact of recent
advances in imaging modalities.
Methods: We searched the National Cancer Database for patients
with NSCLC diagnosed between the calendar years 1998 and 2006
for which staging information was available.
Results: Among the 877,518 patients diagnosed with NSCLC during
the study period, staging information was available for 813,302 patients
(92.6%). We observed a change in stage distribution between the years
2000 and 2001, with a decrease in stage I, from 27.5 to 24.8%, and a
corresponding increase in stage IV, from 35.4 to 38.8%. No significant
changes in stage distribution were noted after 2002.
Conclusion:Our study showed a recent and significant stage migration
in patients with NSCLC. It is likely that increased acceptance and
widespread use of 18fluorodeoxyglucose-positron emission tomography
scan and routine brain imaging could account for these changes.
(J Thorac Oncol. 2010;5: 29–33)
Lung cancer is the leading cause of cancer mortality with anestimated 161,840 annual deaths projected for 2008 in the
United States.1 Non-small cell lung cancer (NSCLC) accounts
for approximately 87% of all patients with lung cancer.2
Retrospective studies have shown a recent change in stage
distribution for NSCLC. In a single institution retrospective
study conducted at the Alvin J. Siteman Cancer Center at
Washington University involving 6118 consecutive patients,
there was a significant increase in the proportion of stage IV
disease from 30% between years 1990 and 1999 to 38% be-
tween years 2000 and 2005.3 In the retrospective analysis in-
volving 12,395 NSCLC patients from the Sacramento region of
the California Cancer Registry, the percentage of stage IV
disease increased from 38.7% between 1994 and 1998 to 47.2%
between 1999 and 2004.4 Although both studies correlated the
stage migration with the increasing use of 18fluorodeoxyglucose
positron emission tomography (FDG-PET), there are some sig-
nificant limitations. These studies included relatively small num-
bers of patients. Moreover, changing pattern of care with regard
to staging procedures and resultant staging distribution from a
tertiary hospital or a regional registry may not truly portray
nationwide changes.
We performed a retrospective study using a large data-
base, representing the majority of patients with the diagnosis of
NSCLC in the United States, to evaluate the trends in stage
distribution over the recent years. The National Cancer Database
(NCDB) is a nationwide oncology database established in 1989
as a joint program of the commission on cancer of the American
College of Surgery and the American Cancer Society. Approx-
imately 70% of all newly diagnosed cases of cancer in the
United States are captured at institutional level through hospital-
based cancer registries and reported to the NCDB.5
METHODS
We queried the NCDB benchmark report for patients with
lung cancer diagnosed between the calendar years 1998 and
2006. Only patients with NSCLC for whom staging information
was available were included in this study. We collected demo-
graphics and staging information for all hospitals combined and
within each hospital category. Most of approved cancer pro-
grams in the NCDB can be broadly classified into three main
categories, including Community Hospital Cancer Programs
(CHCP), Community Hospital Comprehensive Cancer Pro-
grams, and Teaching Hospital Cancer Programs. CHCP and
Community Hospital Comprehensive Cancer Programs are de-
fined by facility accessions of 100 to 649 and 650 or more newly
diagnosed cases of cancer per year, respectively, whereas Teach-
ing Hospital Cancer Programs are facilities associated with
medical schools, required to participate in clinical research and
participate in training residents in at least four areas including
Medicine and Surgery.
Staging system was performed according to the American
Joint Committee on Cancer 5th edition for patients diagnosed
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between 1998 and 2001 and American Joint Committee on
Cancer 6th edition for those diagnosed between 2002 and 2006.
Because there have been no changes between the two staging
classifications, there is no need for adjustments according to the
year of diagnosis.6
RESULTS
Among the 877,518 NSCLC patients diagnosed between
1998 and 2006, 64,206 patients (7.4%) with unknown stage
were excluded, leaving 813,302 patients (92.6%) eligible for
final analysis (Table 1). There were 467,905 men (57.5%) and
345,397 women (42.5%). The majority of patients were white
(84.3%), followed by black (10.4%) and other races (5.3%).
Adenocarcinoma was the most common histology (37.5), fol-
lowed by squamous cell carcinoma (26.8%), other histologies
(26.5%), large-cell carcinoma (5.7%), and bronchioloalveolar
carcinoma (3.5%). Approximately two thirds of patients had
locally advanced (27.6%) or metastatic (38.1%) disease. There
were 782,335 patients (96.4%) classified within one of the three
most common hospital categories and 30,967 (3.8%) classified
as other hospital types.
Between 1998 and 2006, the number of patients enrolled
into the NCDB database increased from 78,412 to 97,889, with
the most significant increase occurring between the years 2000
TABLE 1. Patient Demographics
Parameter Variable Patients, n (%)
Age (yr) 16–49 48,802 (6.0%)
51–70 368,118 (45.3%)
70 396,312 (48.7%)
Gender Male 467,905 (57.5%)
Female 345,397 (42.5%)
Race White 685,296 (84.3%)
Black 84,557 (10.4%)
Other 43,449 (5.3%)
Histology Adenocarcinoma 304,751 (37.5%)
Squamous 214,506 (26.8%)
Large cell 46,270 (5.7%)
BAC 28,852 (3.5%)
Other 215,939 (26.5%)
Stage I 211,459 (26%)
II 67,254 (8.3%)
III 224,624 (27.6%)
IV 309,965 (38.1%)
Hospital type CHCP 129,961 (16.0%)
COMP 402,784 (49.5%)
THCP 249,590 (30.7%)
Other 30,967 (3.8%)
CHCP, Community Hospitals Cancer Programs; COMP, Community Hospital
Comprehensive Cancer Programs; THCP, Teaching Hospital Cancer Programs.
TABLE 2. Changes in Demographic and Stage Distribution for Non-small Cell Lung Cancer Diagnosed Between 1998 and 2006
1998 1999 2000 2001 2002 2003 2004 2005 2006
Patients (n) 78,412 79,127 78,618 94,720 93,621 96,583 95,370 98,962 97,889
Age (yr)
16–49 6.0 6.1 6.2 6.0 6.2 6.1 6.0 5.8 5.6
51–70 46.1 45.4 45.2 45.1 44.9 44.9 45.2 45.3 45.4
70 47.9 48.5 48.6 48.9 48.9 48.9 48.8 48.9 49.0
Gender
Male 59.6 59.0 58.4 58.0 57.4 57.4 56.9 56.3 55.7
Female 40.4 41.0 41.6 42.0 42.6 42.6 43.1 43.7 44.3
Race
White 85.3 85.1 84.9 84.4 84.2 84.0 83.7 83.6 83.5
Black 10.1 10.2 10.0 10.4 10.4 10.6 10.6 10.5 10.7
Other 4.6 4.7 5.1 5.2 5.4 5.4 5.7 5.9 5.8
Histology
Adenocarcinoma 42.5 42.9 44.0 35.9 35.1 34.8 34.5 34.7 35.8
Squamous cell 31.9 31.7 31.4 25.6 24.8 24.0 23.5 23.6 23.8
Large cell 10.5 10.1 9.3 6.2 5.2 4.67 4.0 3.8 3.2
BAC 4.1 4.3 4.4 3.5 3.4 3.2 3.1 3.1 3.1
Other 11.0 11.0 10.9 28.8 31.5 33.4 34.9 34.8 34.1
Hospital
CHCP 15.8 15.9 15.7 15.6 15.9 15.8 16.3 16.3 16.4
COMP 50.0 50.0 49.9 50.1 49.3 49.5 48.9 49.1 49.1
THCP 30.3 30.4 30.7 30.5 31.0 31.0 30.7 30.8 30.6
Other 3.9 3.7 3.7 3.8 3.8 3.7 4.0 3.8 3.9
Known stage
I 27.2 27.2 27.2 25.2 24.8 25.1 25.3 26.2 26.4
II 9.5 9.4 9.2 8.4 8.1 7.8 7.5 7.6 7.6
III 28.6 28.3 27.9 27.9 27.7 27.5 27.4 27.0 26.6
IV 34.7 35.1 35.7 38.6 39.4 39.6 39.8 39.2 39.4
Unknown stagea 7.2 7.2 7.2 6.7 6.7 7.5 10.8 10.7 12.4
Data are given in %.
a Patients with unknown stage are not included in any other demographic evaluation.
CHCP, Community Hospitals Cancer Programs; COMP, Community Hospital Comprehensive Cancer Programs; THCP, Teaching Hospital Cancer Programs.
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and 2001 (Table 2). Changes in demographic patterns were
mostly gradual, with a slight increase in the percentage of elderly
patients and increased proportion of women and other races
including Asians and Hispanics. Starting in 2001, there was a
significant shift in the reported histology, with an abrupt increase
in the percentage of patients diagnosed with other histologies.
Overall, the rates of patients according to hospital type remained
constant throughout the study period.
There was a steady change in stage distribution from 1998
to 2000, with the progressive increase in stage IV and decrease
in stage III NSCLC. Between the years 2000 and 2001, there
was a sharp decrease in stage I NSCLC with corresponding
increase in stage IV. The proportion of patients with stage IV
NSCLC reached a plateau after 2002 (Figure 1). During this
time, the percentage of patients with unknown stage changed
most significantly between the years 2000–2001 (7.2–6.7%),
2002–2003 (6.7–7.5%), and 2003–2004 (7.5–10.8%).
Despite differences in baseline stage distribution among
the three hospital categories, notably with the increased percent-
age of patients with stage IV in CHCP, the change in stage
distribution was similar across the hospital subtypes, with the
most significant increase in the proportion of stage IV patients
between the years 2000 and 2001 (Table 3 and Figure 2).
DISCUSSION
This large registry-based analysis confirms the recently
described changes in stage distribution for patients with NSCLC,
with an increasing proportion of stage IV NSCLC after the year
2000. Despite the increased number of patients accrued between
2000 and 2001, this factor by itself is unlikely to be the a
significant contributor for the stage migration, because the pa-
tient characteristics including age, gender, race, and hospital
type changed gradually over the study period, without sharp
variations. Furthermore, the significant 2.9% increase in the
percentage of patients with stage IV NSCLC in the 2000–2001
period was preceded by a 1% increase in the 1998–2000 period
and succeeded by a 1% increase in the 2001–2003 period despite
similar number of patients within both preceding and succeeding
periods. The only significant demographic change occurring
between 2000 and 2001 was the increased percentage of patients
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FIGURE 1. Percentage of stage IV non-small cell lung can-
cer (NSCLC) from 1998 to 2006.
TABLE 3. Stage Distribution for Non-small Cell Lung Cancer According to Hospital Category for
Patients Diagnosed Between 1998 and 2006
1998 1999 2000 2001 2002 2003 2004 2005 2006
CHCP
I 25.1 24.8 23.9 22.7 22.2 22.4 22.2 22.7 22.3
II 9.4 9.5 9.3 8.7 8.3 7.6 7.7 7.4 7.9
III 29.5 29.4 29.7 28.9 29.2 28.8 28.6 28.4 28.3
IV 36.0 36.3 37.1 39.7 40.3 41.2 41.5 41.5 41.5
COMP
I 27.2 27.6 27.3 25.1 24.9 25.5 25.6 26.3 26.9
II 9.6 9.4 9.0 8.4 8.2 7.8 7.5 7.8 7.6
III 28.9 28.3 27.5 27.7 27.5 27.3 27.2 26.8 26.2
IV 34.3 34.7 35.2 38.8 39.4 39.4 39.7 39.1 39.3
THCP
I 28.4 27.9 28.8 26.3 26.1 26.1 26.6 28.1 28.2
II 9.7 9.6 9.1 8.4 8.1 7.8 7.4 7.4 7.4
III 27.5 27.6 27.0 27.6 26.9 26.9 26.8 26.5 26.1
IV 34.4 34.9 35.1 37.7 38.9 39.2 39.2 38.0 38.3
Data are given in %.
CHCP, Community Hospitals Cancer Programs; COMP, Community Hospital Comprehensive Cancer Programs; THCP, Teaching
Hospital Cancer Programs.
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with other histologies, which precludes further evaluations ac-
cording to histologic subtype.
It is likely that these changes in stage distribution
reflect the widespread adoption of FDG-PET scans and mag-
netic resonance imaging (MRI) of the brain. In January 1998,
the Centers for Medicare and Medicaid Services, formerly
known as US Health Care Finance Administration, approved
FDG-PET scan for Medicare reimbursement in the initial
staging of patients with lung cancer and for the characteriza-
tion of solitary pulmonary nodules. This indication was
expanded in July 2001 to include diagnosis, staging, and
restaging in lung cancer leading to widespread adoption of
FDG-PET scan in staging of newly diagnosed NSCLC.7,8 FDG-
PET is currently recommended for the staging of NSCLC by the
three main oncology guidelines, including the American Society
of Clinical Oncology, the American Thoracic Society, and the
National Comprehensive Cancer Network.9–11
Multiple studies have shown a detection rate of unsus-
pected metastases in approximately 10 to 15% of patients
with NSCLC.12–17 This upstaging observed in prospective
studies probably translates into a smaller but real change in
the overall percentage of patients with stage IV NSCLC in a
large population of unselected patients.
An additional contributing factor for the changing distri-
bution is the increasing indication for the use of brain imaging.
Using MRI instead of CT scan of the brain may also contribute
to the increase in the diagnosis of intracranial metastases be-
cause MRI may detect smaller lesions.18,19 The impact of iso-
lated brain metastases is small but probably not negligible. Any
impact of brain imaging on the increase of stage IV NSCLC at
presentation would be from asymptomatic patients with other-
wise stage I or II disease, because patients with symptoms or
abnormal neurologic findings are almost universally staged with
brain CT scan or MRI and most patients with stage III NSCLC
undergo brain imaging before aggressive therapy.
The NCBD is the largest population study available in
the United States, capturing approximately 70% of all newly
diagnosed lung cancer cases and representing all regions and
states in the country. The proportion of patients with un-
known stage is only 8%, allowing a more accurate evaluation
of staging proportions. For patients with breast, colorectal,
lung, or prostate cancer diagnosed in 1992, a comparison
between the Surveillance, Epidemiology, and End Results
and NCDB programs showed only a marginal difference
between the two databases. Some of the notable differences
included a more complete description of ethnicity in the
Surveillance, Epidemiology, and End Results database and
improved report on stage and tumor grade by the NCDB.20
Although the NCDB does not provide information on
the use of FDG-PET scan, it is well known that this imaging
modality has become widely available and is frequently used
in the staging of NSCLC. A survey using data from a large
private insurer in California found a sixfold increase in
FDG-PET utilization between the years 2000 and 2004,
increasing from 2.4 to nearly 12 per 10,000 enrollees.23
Nationwide, the number FDG-PET or FDG-PET/CT com-
bined tests performed in the United States has increased from
approximately 200,000 in the year 2000 to approximately 1.5
million in 2006.22
The shifting of patients with earlier disease to advanced
disease due to an unexpected discovery of metastases may have
significant clinical implications. One of them is the “Will Rogers
phenomenon,” an apparent paradox observed when moving one
element from one group to another raises the average for both
the donor and recipient sets.23 In this case, transferring the
previously undetectable metastatic disease from earlier stages to
advanced stages may increase the survival in patients with
earlier stages because of the removal of false earlier stage
patients, a population with known worse prognosis. Similarly,
the incorporation of patients with decreased tumor burden to the
overall pool of metastatic disease may also increase the survival
for the recipient set, given their expected better outcomes com-
pared with widespread metastatic disease, as previously ob-
served in two retrospective studies.3,4
In summary, we have clearly shown a significant stage
migration for NSCLC, with the most dramatic shift occurring
between the years 2000 and 2001. The most likely explana-
tion is the increased acceptance and widespread use of PET
scan during staging, with a possible small contribution of
increased imaging of the brain. Future studies should take in
account this stage distribution and be careful when using
comparison with historical controls.
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